Is the price fair?
What CRL's price assumes
Today's price asks for 8.1% free cash flow growth a year; over the last three years Charles River Laboratories delivered 8.6%, less than the record.
1.93
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 4.2%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +8.1%
Growth the price implies · The price pays for +8.1% free cash flow growth a year for a decade; the business has delivered +8.6% a year over the last three.
- Price / book
- 2.65
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 2.65
- EV / EBIToperating margin 2.3%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $371M
- Market capitalisation
- $8.91B
- 3-year revenue growth
- −1.5%
- 3-year free cash flow growth
- +8.6%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #17 of 29 by Smart Score